Clinical study of China officinalis in the view of classical systemic homeopathy during COVID-19 epidemic in São Paulo

• Published in: International journal of high dilution research Vol. 20; no. 1; pp. 13 - 14
• Main Authors: Mendes, Maria Filomena Xavier, Takeuti, Isabella Sebusiani Duarte, Melo, Luciana Valentini, Santos, Leticia Marilia de Almeida Werneck, Barbas, Danielle da Silva, Cabo, Domingos José Vaz, Brunelli, William, Strastis, Hristos, Lino, Renata Rodrigues Garcia, Mourão, Leila Cristina dos Santos, Oliveira, Adriana Passos, Gosik, Maria Solange
• Format: Journal Article
• Language: English
• Published: 28-03-2021
• ISSN: 1982-6206; 1982-6206
• DOI: 10.51910/ijhdr.v20i1.1085

Background: Brazilian Ministry of Health has reported 5.273.954 cases and 154.837 deaths from COVID-19 on October 20th, 2020. The first case of COVID-19 in Brazil occurred on February 26th, in São Paulo state. A total of 351.877 cases and 13.331 deaths were reported only in the city of São Paulo on October 20th. This scenario has severe health, economic, and social impact, as in other countries. Therefore, treatment strategies are urgently needed, such as Homeopathy that has shown excellent results in several epidemics. Aims: This study aims to describe the health signs and symptoms of some healthcare and essential professionals during the use of China officinalis. Methodology: Participants were professionals of the Server Public Municipal Hospital of São Paulo (HSPM), the Nossa Senhora Rainha da Paz Association (RP), and The Padre Bento Hospital (HPB). The homeopathic intervention was C. officinalis 6CH and a dosage of six drops per day. The study design was a time series with analysis by questionnaire before and after using homeopathic medicine. Statistical analyses were done by the McNemar test to compare qualitative data paired with a significance level of 5%. Ethical approval is CAAE 31802720.0.0000.5442. Results and discussion: Among the HSPM and RP participants, 83,1% did not develop symptoms while using C. officinalis and 16,9% developed symptoms while using C. officinalis. Among the HPB participants, 87,8 % did not develop symptoms while using C. officinalis and 12,2 % developed symptoms while using C. officinalis. . During the usage of C. officinalis, covid19-like symptoms were reduced with a significant difference (p<0.05). Among the symptomatic, none of the participants needed intensive care hospitalization, supplemental oxygen, or intubation. Conclusion: C. officinalis was very acceptability by participants, and its use during the coronavirus pandemic contributed to health promotion.